Related Experiment Video
Updated: Mar 5, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles
Keyu Li1, Yaliang Lan1, Jiabei Wang1
11 Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Abstract:
Chimeric antigen receptor-engineered T cells therapy has become the hottest topic of immunotherapy, as its great successes achieved in treating refractory hematological malignancies. These successes also paved the road to novel strategies of treating various solid tumors including liver cancer. Many specific proteins can be expressed aberrantly in liver cancers; therefore, a series of experimental and clinical researches exploring chimeric antigen receptor-engineered T cells and liver cancer are in progress, acquiring obvious antitumor effect and revealing its feasibility in treating liver cancer. However, lots of challenges and obstacles are emerging simultaneously, such as low infiltration, side effects, safety of chimeric antigen receptor-engineered T cells, and limited data of studies or clinical trials. Researchers have been working out many innovative ways to directly stroke these obstacles, theoretically or practically. This review focuses more on the progress and obstacles from chimeric antigen receptor-engineered T cells therapy to treat liver cancer, summarizing new breakthroughs in shooting those obstacles, meanwhile, hoping to provide enlightenment to this promising immunotherapeutic method.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for liver cancer treatment, overcoming challenges like low infiltration and safety concerns. Ongoing research aims to refine this immunotherapy for solid tumors.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR)-engineered T-cell therapy has shown significant success in hematological malignancies.
- This success has spurred interest in applying CAR T-cell therapy to solid tumors, including liver cancer.
Purpose of the Study:
- To review the progress and challenges of CAR T-cell therapy for liver cancer.
- To highlight innovative strategies addressing current obstacles and provide insights for future development.
Main Methods:
- Review of experimental and clinical research on CAR T-cell therapy in liver cancer.
- Analysis of challenges such as T-cell infiltration, side effects, and safety.
- Identification of emerging solutions and breakthroughs.
Main Results:
- CAR T-cell therapy demonstrates feasibility and antitumor effects in liver cancer models.
- Key challenges identified include poor T-cell infiltration, potential side effects, and safety concerns.
- Innovative approaches are being developed to overcome these limitations.
Conclusions:
- CAR T-cell therapy holds promise for treating liver cancer.
- Addressing challenges in T-cell infiltration, safety, and efficacy is crucial for clinical translation.
- Continued research and innovative strategies are essential for advancing this immunotherapeutic approach.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019